On Monday, Alcon reached a key performance benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 83, up from 80 the day before.
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best-performing stocks often have an RS Rating of above 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Alcon is working on a consolidation with a 101.10 buy point. See if the stock can clear the breakout price in heavy volume.
While earnings-per-share growth decreased in the prior quarter from 23% to 3%, sales grew 6%, up from 5% in the prior report. The company is expected to report its latest earnings and sales numbers on or around May 14.
Alcon earns the No. 14 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
